

1 **Digital nuclear morphometry correlates to BAP-1 expression, gene expression**  
2 **class and metastasis-free survival in uveal melanoma**

3 Christina Herrspiegel<sup>1,2</sup>, Thonnie Rose O. See<sup>3</sup>, Pia R. Mendoza<sup>4</sup>, Hans E.

4 Grossniklaus<sup>3</sup>, and Gustav Stålhammar\*<sup>1,2</sup>

5 <sup>1</sup>St. Erik Eye Hospital, Stockholm, Sweden

6 <sup>2</sup>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, and

7 <sup>3</sup>Departments of Ophthalmology and Pathology, Emory University School of  
8 Medicine, Atlanta, Georgia, USA.

9 <sup>4</sup>Department of Pathology and Laboratory Medicine, Emory University School of  
10 Medicine, Atlanta, Georgia, USA.

11

12 \*Corresponding author

13 Gustav Stålhammar, M.D. Ph.D. FEBO

14 Oncology and Pathology service, St. Erik Eye Hospital

15 Department of Clinical Neuroscience, Karolinska Institutet

16 Polhemsgatan 50, 112 82

17 Stockholm, Sweden

18 Email: [gustav.stalhammar@ki.se](mailto:gustav.stalhammar@ki.se)

19 Phone: +46 8 672 30 00

20

21 **ABSTRACT**

22 Cytologic features such as the shape and size of tumor cells can predict metastatic  
23 death in uveal melanoma, but suffer from poor reproducibility. In this study, we  
24 investigate the interobserver concordance of digital morphometry, and correlate the  
25 results with established prognostic markers. The average number of cells analyzed in  
26 each of 27 tumors, was 1957 (SD 349). Mean time consumption was less than 2.5  
27 minutes per tumor. Identical morphometric classification was obtained for  $\geq 85\%$  of  
28 tumors in all twelve evaluated morphometric variables ( $\kappa$  0.70–0.93). The mean  
29 nucleus area, nucleus perimeter, nucleus max caliper and nucleus to cell area ratio  
30 were significantly greater in tumors with low nuclear BRCA associated protein-1  
31 expression (nBAP-1) and gene expression class 2. Patients had significantly shorter  
32 metastasis-free survival if their tumors had low nBAP-1 expression (Log-Rank  
33  $p=0.002$ ), gene expression class 2 (Log-Rank  $p=0.004$ ) or tumor cell nuclei with long  
34 max calipers (Log-Rank  $p=0.004$ ) as defined in a training cohort and then tested in a  
35 validation cohort. We conclude that digital morphometry can be fast and highly  
36 reproducible, that for the first time, morphometry parameters can be objectively  
37 quantitated in thousands of cells at a time, and that variables describing the shape and  
38 size of the nuclei correlate to nBAP-1 expression, gene expression class and prognosis  
39 in uveal melanoma.

## 40 **1. Introduction**

41 Uveal melanoma is the most common primary intraocular malignancy in adults  
42 (Singh et al., 2014). Less than 5 % of patients have clinically detectable metastases at  
43 the time of diagnosis (Singh et al., 2014). At a later stage however, up to 45 % of  
44 patients will develop metastases even if the eye containing the tumor has been  
45 removed (Kujala et al., 2003). Once macrometastases develop, there is no effective  
46 treatment and median patient survival is only 4-12 months (Augsburger et al., 2009;  
47 Carvajal et al., 2016).

48 Several methods for prognostication are in clinical use. Tumor thickness,  
49 diameter, location in the eye and presence of distant metastases determine tumor stage  
50 (Arnljots et al., 2018; Kivelä et al., 2017). Loss of chromosome 3 has a high positive  
51 and negative predictive value for metastasis (Bornfeld et al., 1996). Commercial gene  
52 tests based on the expression of 12 classifier genes have been developed and show  
53 excellent prognostic utility in separation of class 1 tumors with low metastatic risk  
54 from class 2 tumors with high metastatic risk (Onken et al., 2012). Furthermore, we  
55 have previously shown the prognostic utility of manual (Szalai et al., 2018) and  
56 digital image analysis-based (Stålhammar et al., 2019) determination of the level of  
57 nBAP-1.

58 In 1931, Callender described six types of uveal melanoma based on cytologic  
59 features such as cell shape and the size of the nucleus (Callender, 1931). The original  
60 classification could accurately predict metastatic death, but suffered from substantial  
61 intra- and interobserver discordance (Coleman et al., 1996; Gamel et al., 1992). After  
62 several modifications, the morphological classification of uveal melanoma now rely  
63 on assessments of the proportion of epitheloid tumor cells (McLean et al., 1983;

64 Seddon et al., 1987). Examination of cytological features still require a high level of  
65 cytologic expertise and suffer from poor reproducibility (Gamel et al., 1992).  
66 Computer-assisted methods have therefore been proposed as a way of facilitating  
67 these assessments. In 1982, Gamel *et al.* found that 13 of 18 nuclear and nucleolar  
68 features correlated significantly with patient mortality when evaluated with a digitizer  
69 superimposed on microscopic images at a rate of 100 cells per hour (Gamel et al.,  
70 1982). Since then, computers have improved manifold in terms of their computing  
71 power, cost and the number and scope of software applications and we can now  
72 analyze a dozen of variables or more in thousands of cells per minute on inexpensive  
73 off-the-shelf laptop computers (Stålhammar et al., 2016; Stålhammar et al., 2018).

74         Consequently, we see an opportunity to analyze cell morphometry features  
75 with digital image analysis and compare these to other prognostic factors including  
76 nBAP-1 expression in uveal melanoma patients from one American and one European  
77 referral center.

78

## 79 **2. Methods**

### 80 *2.1. Patients and Samples*

81 The study adhered to the tenets of the Declaration of Helsinki. Methods were carried  
82 out in accordance with the relevant guidelines and regulations. The protocol for  
83 collection of specimens and data from St. Erik Eye Hospital, Stockholm, Sweden was  
84 approved by the regional ethical review board in Stockholm, and the protocol for  
85 collection of specimens and data from Emory Eye Center, Atlanta, GA, USA by the  
86 Emory Institutional Review Board.

87 Patients were identified in the archives of the Oncology and Pathology  
88 service, St. Erik Eye Hospital and L.F. Montgomery Ophthalmic Pathology  
89 Laboratory, Emory Eye Center. Inclusion criteria were: 1) Enucleation performed  
90 before December 2017, 2) Histologically proven uveal melanoma, 3) paraffin block  
91 available, 4) gene expression classification available, 5) clinicopathological data  
92 available, including tumor thickness, diameter, location, T-category and cell type, 6)  
93 follow-up data available, 7) sufficient tissue for BAP-1 immunohistochemistry.  
94 Exclusion criteria were: 1) Prior history of plaque brachytherapy, proton beam  
95 irradiation and/or transpupillary thermotherapy, and 3) tumor fully necrotic or fully  
96 hemorrhagic. 27 patients met the criteria. Our follow-up data was confirmed and  
97 further extended in telephone interviews with patients or relatives. Informed consent  
98 was obtained from all participants.

99 In order to establish optimized morphometry thresholds for the distinction of  
100 metastatic versus non-metastatic disease we divided our 27 patients into one training  
101 and one validation cohort. When determining the relative size of the training and  
102 validation cohorts, we considered previous research indicating that the ratio should be  
103 inversely proportional to the square root of the number of free adjustable parameters  
104 (Guyon, 1997). As we only evaluated one morphometric variable at a time, we set the  
105 ratio to 1:1. 13 patients were randomized to the training cohort and 14 to the  
106 validation cohort.

107

## 108 *2.2. Immunohistochemistry*

109 The paraffin blocks were cut into 4  $\mu\text{m}$  sections, pretreated in EDTA-buffer at pH 9.0  
110 for 20 minutes and incubated with mouse monoclonal antibodies against BAP-1

111 (clone C-4, Santa Cruz Biotechnology, Dallas, Texas, USA) and a red chromogen,  
112 and finally counterstained with haematoxylin and rinsed with deionized water. The  
113 deparaffinization, pretreatment, primary staining, secondary staining and  
114 counterstaining steps were run in a Bond III automated IHC/ISH stainer (Leica,  
115 Wetzlar, Germany). Dilutions between 1:20 and 1:500 had been evaluated before  
116 selecting 1:40.

117

### 118 *2.3. Digital image analysis*

119 After sectioning and staining, all glass slides were digitally scanned to the .ndpi file  
120 format at  $\times 400$ , using identical digital scanners at both institutions (Nano Zoomer 2.0  
121 HT, Hamamatsu Photonics K.K., Hamamatsu, Japan). The digital image analysis  
122 (DIA) software used was the QuPath Bioimage analysis v. 0.2.0 m4 (Bankhead et al.,  
123 2017). The software was run on a standard off-the-shelf laptop computer (Apple Inc.  
124 Cupertino, CA).

125 For assessment of the level of nBAP-1 expression, one positive cell (red  
126 chromogen in nucleus) and one negative cell (haematoxylin but no red chromogen in  
127 nucleus) was calibrated in each digitally scanned tissue section. All other parameters  
128 were left at default in order to limit time consumption and maintain ease of use.  
129 Tumors were then screened under low magnification ( $40\times$ ) and the area exhibiting the  
130 most intense nBAP-1 staining selected for grading. Nuclear immunoreactivity was  
131 evaluated at  $200\times$ , in a circular 0.5 mm-diameter region of interest (corresponding to  
132 the field of view in a light microscope with a  $400\times$  objective) by automatic  
133 classification (positive cell detection). Based on previous publications, the nBAP-1  
134 expression was classified as “high” if immunoreactivity was detected in  $>30\%$  of

135 tumor cells within the region of interest, and “low” if it was detected in  $\leq 30\%$  of  
136 tumor cells (See et al., 2019; Stålhammar et al., 2019; Szalai et al., 2018).

137 A workflow for morphometric analysis was then created, including the  
138 following steps for each tumor: A) Identification of all cells within the region of  
139 interest, using the software’s cell detection function with the following settings:  
140 Background nucleus radius  $8\ \mu\text{m}$ , median filter radius  $0\ \mu\text{m}$ , sigma  $1.5\ \mu\text{m}$ , minimum  
141 nucleus area  $7.5\ \mu\text{m}^2$ , maximum nucleus area  $200\ \mu\text{m}^2$ , threshold 0.1, max  
142 background intensity 2 and cell expansion  $5\ \mu\text{m}$ . B) Measurement in each detected  
143 cell in each region of interest of the following 12 cell morphometric variables: 1)  
144 Nucleus area ( $\mu\text{m}^2$ ). 2) Nucleus perimeter ( $\mu\text{m}$ ). 3) Nucleus circularity. 4) Nucleus  
145 max caliper ( $\mu\text{m}$ ). 5) Nucleus min caliper ( $\mu\text{m}$ ). 6) Nucleus eccentricity. 7) Cell area  
146 ( $\mu\text{m}^2$ ). 8) Cell perimeter ( $\mu\text{m}$ ). 9) Cell circularity. 10) Cell max caliper. 11) Cell min  
147 caliper. 12) Nucleus to cell area ratio (figure 1).

148 Tumor areas with intense inflammation, heavy pigmentation, bleeding,  
149 necrosis or poor fixation were avoided. nBAP-1 classification and morphometric  
150 analysis was performed blinded to all other patient data including outcome. For  
151 measurement of interobserver concordance, two human observers performed the  
152 digital morphometry (morphometric variable above or below median value) and  
153 nBAP-1 classification (high or low) independently and blinded to patient outcomes.

154

#### 155 *2.4. Gene expression classification*

156 Tumor tissue samples were obtained from freshly enucleated eyes by fine needle  
157 aspiration. The contents of the needle hub were transferred into one of two RNase-  
158 free cryovials. Using the same needle, extraction buffer from the second cryovial was

159 aspirated and expelled into the first. This was then placed in a specimen bag,  
160 immediately frozen to  $-80^{\circ}\text{C}$  and shipped on dry ice for gene expression classification  
161 based on 12 discriminating genes (*HTR2B*, *ECM1*, *RAB31*, *CDH1*, *FXR1*, *LTA4H*,  
162 *EIF1B*, *ID2*, *ROBO1*, *LMCD1*, *SATB1*, and *MTUS1*) and 3 control genes (*MRPS21*,  
163 *RBM23*, and *SAPI30*) at a commercial laboratory (Castle Biosciences Inc.  
164 Friendswood, TX, USA). Expression levels of the gene products are used to  
165 categorize tumors as either class 1 with low metastatic risk, or class 2 with high  
166 metastatic risk (Onken et al., 2012).

167

### 168 *2.5. Statistical methods*

169 Differences with a  $p < 0.05$  were considered significant, all p-values being two-sided.  
170 The deviation of all clinicopathological variables from normal distribution was  
171 statistically significant, when evaluated by the Shapiro–Wilk test ( $p < 0.05$ ). For  
172 statistical tests of these variables, we therefore used the Mann-Whitney *U* test, which  
173 does not assume normally distributed data. The deviation of all morphometric  
174 variables from normal distribution was however not statistically significant ( $p > 0.05$ ),  
175 why we used Students T-tests for these. For comparisons of categorical variables,  
176 two-by-two tables and Fisher’s exact test were used. For correlation to Cox  
177 Proportional Hazards for metastasis and Kaplan-Meier metastasis-free survival,  
178 patients were split into two groups based on 1) the median value of each  
179 morphometric variable, and 2) receiver operating characteristics (ROC) in the training  
180 cohort, with equal emphasis on sensitivity and specificity for the development of  
181 metastasis. The thresholds established in the training cohort were then tested in the  
182 validation cohort. In evaluation of interobserver concordance, the percentage of



183 identically classified cases and Cohen's kappa statistics ( $\kappa$ ) were computed (Cohen,  
184 1960). Metastasis-free follow-up was defined as the time in months from enucleation  
185 to the last occasion patients without metastases was seen or in contact alive. All  
186 statistical analyses were performed using IBM SPSS statistics version 25 (Armonk,  
187 NY, USA).

188

### 189 **3. Results**

#### 190 *3.1. Descriptive statistics*

191 The mean age at enucleation of patients included in this study was 66 years (SD 15).  
192 Of 27 patients, 15 were men and 12 women. 25 tumors originated in the choroid and 2  
193 in the ciliary body. The cell type was mixed in 18 patients, spindle in 5 and epitheloid  
194 in 4. Mean tumor thickness was 8.6 mm (SD 3.7) and mean diameter 15.8 mm (SD  
195 4.8). 12 tumors were of gene expression class 2 and 15 of class 1a or 1b. 14 tumors  
196 had low nBAP-1 expression and 13 high. Mean metastasis-free follow-up time was 47  
197 months (SD 76, Table 1).

198 The average number of cells analyzed in each tumor was 1957 (SD 349),  
199 which took an average of 74 seconds (SD 21) for nBAP-1 classification and 71  
200 seconds (SD 17) for morphometric analysis, adding up to 145 seconds or nearly two-  
201 and-a-half minutes per tumor.

202

#### 203 *3.2. Interobserver concordance*

204 Identical nBAP-1 classification was obtained for 25 of 27 tumors (93 %), yielding a  
205 Cohen's kappa statistic indicating almost perfect agreement ( $\kappa=0.85$ ).

206 Identical morphometric classification (morphometric variable above/below  
207 median value) was obtained for  $\geq 85$  % of tumors in all 12 variables, yielding  
208 substantial or almost perfect agreement ( $\kappa$  0.70–0.93, Table 2).

209

### 210 *3.3. Morphometry versus nBAP-1 expression and gene expression class*

211 The mean nucleus area, nucleus perimeter, nucleus max caliper and nucleus to cell  
212 area ratio were significantly greater in tumors with low nBAP-1 expression. Nucleus  
213 circularity, nucleus min caliper, nucleus eccentricity and cell area, cell perimeter, cell  
214 circularity, cell max and min caliper were however not significantly different (Table  
215 3a).

216 Similarly, the mean nucleus area, nucleus perimeter, nucleus max caliper and  
217 nucleus to cell area ratio, but not the other morphometric variables, were significantly  
218 greater in tumors of gene expression class 2 (Table 3b).

219

### 220 *3.4. Adjusted thresholds*

221 The 4 morphometric variables that correlated to nBAP-1 and gene expression class  
222 were analyzed with ROC, with equal emphasis on sensitivity and specificity for the  
223 development of metastasis. Mean nucleus area achieved an area under the curve  
224 (AUC) of 0.67 (sensitivity 67 %, specificity 50 %,  $p=0.40$ ) at threshold  $27.5 \mu\text{m}^2$ ;  
225 Mean nucleus perimeter achieved an area under the curve (AUC) of 0.73 (sensitivity  
226 67 %, specificity 70 %,  $p=0.24$ ) at threshold  $21.5 \mu\text{m}$ ; Mean nucleus max caliper  
227 achieved an area under the curve (AUC) of 0.80 (sensitivity 67 %, specificity 90 %,  
228  $p=0.13$ ) at threshold  $8 \mu\text{m}$ ; and mean nucleus to cell area ratio achieved an area under

229 the curve (AUC) of 0.60 (sensitivity 67 %, specificity 50 %, p=0.61) at threshold 0.28  
230 (figure 2).

231

### 232 *3.5. Regression analysis and survival*

233 In univariate Cox proportional hazards analyses of nucleus area, nucleus perimeter,  
234 nucleus max caliper and nucleus to cell area ratio, none was an individual predictor of  
235 metastasis (Table 4).

236 In Kaplan-Meier analysis, patients had significantly shorter metastasis-free  
237 survival if their tumors had low nBAP-1 expression (Log-Rank p=0.002) or gene  
238 expression class 2 (Log-Rank p=0.004), but not if they had a mean nucleus area,  
239 nucleus perimeter, nucleus max caliper and nucleus to cell area ratio greater than the  
240 median (Log-Rank p=0.20–0.83). When using the thresholds established in the  
241 training cohort, mean nucleus max caliper > 8  $\mu\text{m}$  was associated with metastasis-free  
242 survival (Log-Rank p=0.05), whereas the other ROC-adjusted variables did not  
243 separate groups with significant survival differences (Log-rank p=0.18–0.95, figure  
244 3).

245

## 246 **4. Discussion**

247 In this study, we have shown that digital image analysis of uveal melanoma cell  
248 morphometry can be fast and highly reproducible, and that variables describing the  
249 shape and size of the nuclei correlate to nBAP-1 expression as well as gene  
250 expression class. Patients with tumors that had large nuclei, as defined by their max  
251 caliper, had significantly worse prognosis. On the other hand, no variable describing  
252 the shape and size of the entire tumor cell correlated to the established prognostic

253 factors, indicating that for prognosis, the morphological characteristics of tumor  
254 nuclei are more important.

255 The prognostic importance of cell morphology is by no means a novel  
256 discovery. However, reproducibility, time consumption and level of expertise  
257 required to make reliable assessments of morphometry have limited its utility.  
258 Modern user-friendly digital image analysis techniques offer an attractive solution to  
259 these problems, and for the first time we can now objectively quantitate morphometry  
260 parameters in thousands of cells at a time.

261 In turn, changes to the size and shape of tumor cells are but a consequence of  
262 changes in the genotype. As found by Onken *et al.* the helix-loop-helix inhibitor *ID2*  
263 suppress the epithelial phenotype associated with an enlarged nucleus (Onken *et al.*,  
264 2006). Loss of *ID2* up-regulates the epithelial adhesion molecule E-cadherin, which in  
265 turn promotes the anchorage-independent cell growth required for metastasis.  
266 Consequently, we regard the morphometric characteristics investigated here as  
267 biomarkers of the state of the genotype.

268 Limitations of this study include a small sample size. Inclusion of a larger  
269 number of patients may have revealed additional significant differences. This was  
270 however prevented, primarily by the lack of tumors in our archives for which gene  
271 expression classification was available. Far-reaching conclusions from our survival  
272 analysis are thereby precluded. Substantial investments in digital scanning capacity is  
273 required before the method presented here can be used. The time consumption  
274 specified will most likely be longer for users without general experience in the  
275 operation of home computers, and does not include preanalytical operations such as  
276 digital scanning and loading and unloading of glass slides. Last, our sample is not

277 representative of all patients with uveal melanoma. We have only investigated the  
278 feasibility of digital morphometry in enucleated specimens without previous plaque  
279 brachytherapy. A large proportion of patients with uveal melanoma undergo primary  
280 plaque brachytherapy or proton beam radiotherapy, and may never require  
281 enucleation. It remains unclear if the digital morphometry characteristics of small  
282 uveal melanomas is different from the relatively large tumors investigated here.  
283 Accordingly, we encourage future studies to confirm these results in larger cohorts  
284 that includes smaller tumors .

285

## 286 **Funding**

287 This work was supported in part by Cancerfonden, Karolinska Institutet (Karolinska  
288 Institutets stiftelsemedel för ögonforskning) and Stockholm County Council  
289 (Stockholms läns landsting).

290

291

## 292 **References**


- 293 Arnljots, T.S., Al-Sharbaty, Z., Lardner, E., All-Eriksson, C., Seregard, S.,  
294 Stålhammar, G., 2018. Tumour thickness, diameter, area or volume? The prognostic  
295 significance of conventional versus digital image analysis-based size estimation  
296 methods in uveal melanoma. *Acta Ophthalmol* 96, 510-518.
- 297 Augsburger, J.J., Corrêa, Z.M., Shaikh, A.H., 2009. Effectiveness of  
298 Treatments for Metastatic Uveal Melanoma. *American Journal of Ophthalmology*  
299 148, 119-127.
- 300 Bankhead, P., Loughrey, M., Fernández, J., Dombrowski, Y., McArt, D.,  
301 Dunne, P., McQuaid, S., Gray, R., Murray, L., Coleman, H., James, J., Salto-Tellez,  
302 M., Hamilton, P., 2017. QuPath: Open source software for digital pathology image  
303 analysis. *Sci Rep* 7, 16878-16878.
- 304 Bornfeld, N., Prescher, G., Becher, R., Hirche, H., Jöckel, K.H., Horsthemke,  
305 B., 1996. Prognostic implications of monosomy 3 in uveal melanoma. *The Lancet*  
306 347, 1222-1225.

- 307 Callender, G., 1931. Malignant Melanotic tumors of the eye. A study of  
308 histologic types in 111 cases. *Trans. Am. Acad. Ophthalmol. Otolaryngol.* 36, 131-  
309 142.
- 310 Carvajal, R.D., Schwartz, G.K., Tezel, T., Marr, B., Francis, J.H., Nathan,  
311 P.D., 2016. Metastatic disease from uveal melanoma: treatment options and future  
312 prospects. *British Journal of Ophthalmology*.
- 313 Cohen, J., 1960. A Coefficient of Agreement for Nominal Scales. *Educational*  
314 *and Psychological Measurement* 20, 37-46.
- 315 Coleman, K., Baak, J.P.A., van Diest, P.J., Mullaney, J., 1996. Prognostic  
316 Value of Morphometric Features and the Callender Classification in Uveal  
317 Melanomas. *Ophthalmology* 103, 1634-1641.
- 318 Gamel, J.W., McCurdy, J.B., McLean, I.W., 1992. A comparison of  
319 prognostic covariates for uveal melanoma. *Investigative ophthalmology & visual*  
320 *science* 33, 1919.
- 321 Gamel, J.W., McLean, I.W., Greenberg, R.A., Zimmerman, L.E., Lichtenstein,  
322 S.J., 1982. Computerized histologic assessment of malignant potential: A method for  
323 determining the prognosis of uveal melanomas. *Human Pathology* 13, 893-897.
- 324 Guyon, I., 1997. A scaling law for the validation-set training-set size ratio. *At&t Bell*  
325 *Laboratories, Berkeley California*, pp. 1-11.
- 326 Kivelä, T., Simpson, E.R., Grossniklaus, H.E., Jager, M.J., Singh, A.D.,  
327 Caminal, J.M., Pavlick, A.C., Kujala, E., Coupland, S.E., Finger, P.T., 2017. Uveal  
328 Melanoma, *AJCC Cancer Staging Manual*, 8 ed. Springer, Chicago, pp. 805-817.
- 329 Kujala, E., Mäkitie, T., Kivelä, T., 2003. Very long-term prognosis of patients with  
330 malignant uveal melanoma. *Invest Ophthalmol Vis Sci* 44, 4651-4659.
- 331 McLean, I., Foster, W., Zimmerman, L., Gamel, J., 1983. Modifications of  
332 Callender's classification of uveal melanoma at the Armed Forces Institute of  
333 Pathology. *Am J Ophthalmol* 96, 502-509.
- 334 Onken, M.D., Ehlers, J.P., Worley, L.A., Makita, J., Yokota, Y., Harbour,  
335 J.W., 2006. Functional gene expression analysis uncovers phenotypic switch in  
336 aggressive uveal melanomas. *Cancer research* 66, 4602.
- 337 Onken, M.D., Worley, L.A., Char, D.H., Augsburger, J.J., Correa, Z.M.,  
338 Nudleman, E., Aaberg, T.M., Altaweel, M.M., Bardenstein, D.S., Finger, P.T., Gallie,  
339 B.L., Harocopos, G.J., Hovland, P.G., McGowan, H.D., Milman, T., Mruthyunjaya,  
340 P., Simpson, E.R., Smith, M.E., Wilson, D.J., Wirostko, W.J., Harbour, J.W., 2012.  
341 Collaborative Ocular Oncology Group report number 1: prospective validation of a  
342 multi-gene prognostic assay in uveal melanoma. *Ophthalmology* 119, 1596-1603.
- 343 Seddon, J.M., Polivogianis, L., Hsieh, C.-C., Albert, D.M., Gamel, J.W.,  
344 Gragoudas, E.S., 1987. Death From Uveal Melanoma: Number of Epithelioid Cells  
345 and Inverse SD of Nucleolar Area as Prognostic Factors. *Archives of Ophthalmology*  
346 105, 801-806.
- 347 See, T.R.O., Stålhammar, G., Phillips, S.S., Grossniklaus, H.E., 2019. BAP1  
348 Immunoreactivity Correlates with Gene Expression Class in Uveal Melanoma. *Ocular*  
349 *Oncology and Pathology*, 1-9.
- 350 Shields, C.L., Furuta, M., Thangappan, A., Nagori, S., Mashayekhi, A., Lally,  
351 D.R., Kelly, C.C., Rudich, D.S., Nagori, A.V., Wakade, O.A., Mehta, S., Forte, L.,  
352 Long, A., Dellacava, E.F., Kaplan, B., Shields, J.A., 2009. Metastasis of Uveal  
353 Melanoma Millimeter-by-Millimeter in 8033 Consecutive Eyes. *Archives of*  
354 *Ophthalmology* 127, 989-998.

355 Singh, N., Bergman, L., Seregard, S., Singh, A.D., 2014. Epidemiologic Aspects, in:  
356 Damato, B., Singh, A.D. (Eds.), Clinical Ophthalmic oncology: Uveal tumors, 2 ed.  
357 Springer, Berlin, Heidelberg, pp. 75-87.  
358 Stålhammar, G., Fuentes Martinez, N., Lippert, M., Tobin, N.P., Mølholm, I.,  
359 Kis, L., Rosin, G., Rantalainen, M., Pedersen, L., Bergh, J., Grunkin, M., Hartman, J.,  
360 2016. Digital image analysis outperforms manual biomarker assessment in breast  
361 cancer. *Modern pathology : an official journal of the United States and Canadian*  
362 *Academy of Pathology, Inc* 29, 318.  
363 Stålhammar, G., Robertson, S., Wedlund, L., Lippert, M., Rantalainen, M.,  
364 Bergh, J., Hartman, J., 2018. Digital image analysis of Ki67 in hot spots is superior to  
365 both manual Ki67 and mitotic counts in breast cancer. *Histopathology* 72, 974-989.  
366 Stålhammar, G., See, T.R.O., Phillips, S., Seregard, S., Grossniklaus, H.E.,  
367 2019. Digital Image Analysis of BAP-1 Accurately Predicts Uveal Melanoma  
368 Metastasis. *Translational vision science & technology* 8, 11.  
369 Szalai, E., Wells, J.R., Ward, L., Grossniklaus, H.E., 2018. Uveal Melanoma  
370 Nuclear BRCA1-Associated Protein-1 Immunoreactivity Is an Indicator of Metastasis.  
371 *Ophthalmology* 125, 203-209.

372

## 373 Legends



375 Figure 1. Illustration of cell morphometric measurements. A) Calipers denotes the  
376 largest and smallest diameters of the nucleus and cell. Nucleus eccentricity is a  
377 measure of how much the nucleus deviates from a spherical shape, presented as a  
378 number between 0.00 and 1.00. A completely spherical nucleus have an eccentricity  
379 of 0.00, a nucleus with the shape of an elliptical 3D solid would have an eccentricity

380 of 0.5, whereas a 3D conical distribution would have a value of 1.00. Circularity  
381 compares the perimeter of a shape to the area it contains, and is calculated by four  
382 times  $\pi$  times the area divided by the perimeter squared. The circularity of a circle is  
383 1.00, and less for less circular objects. B) A circular 0.5 mm-diameter region of  
384 interest (corresponding to the field of view in a light microscope with a 400 $\times$   
385 objective) was defined in each tumor. Within this region of interest, each cell was  
386 analyzed for nBAP-1 expression and 12 morphometric variables describing the size  
387 and shape of cells and nuclei. C) The morphometric variables have been automatically  
388 identified within the region of interest shown in B. D and E) In another tumor, cells  
389 have slightly larger, more rounded nuclei with prominent nucleoli, corresponding to  
390 what would be known as epitheloid cells. Cell illustration by iStock.com/Vitalii  
391 Dumma, East Ukraine Volodymyr Dahl National University Scale bars: 100  $\mu\text{m}$ ..  
392

<b><i>n</i></b>	27
<b>Mean age at diagnosis, years (SD)</b>	66 (15)
<b>Sex, n (%)</b>	
Female	15 (56)
Male	12 (44)
<b>Primary tumor location, n (%)</b>	
Choroid	25 (93)
Ciliary body	2 (7)
Iris	0 (0)
<b>Cell type, n (%)</b>	
Spindle	5 (19)
Epitheloid	4 (15)
Mixed	18 (67)
<b>Mean tumor thickness, mm (SD)</b>	8.6 (3.7)



<b>Mean tumor diameter, mm (SD)</b>	15.8 (4.8)
<b>Previous brachytherapy or TTT, n (%)</b>	
No	27 (100)
Yes	0 (0)
<b>AJCC T-category, n (%)</b>	
1	0 (0)
2	7 (26)
3	14 (52)
4	6 (22)
<b>Gene expression class, n (%)</b>	
1a	9 (33)
1b	6 (22)
2	12 (44)
<b>DIA nBAP-1 classification, n (%)</b>	
High	13 (48)
Low	14 (52)
<b>Follow-up months, mean (SD)<sup>§</sup></b>	47 (76)

393 Table 1. Characteristics of patients and tumors included in this study. SD, standard  
 394 deviation. TTT, Transpupillary thermotherapy.

395

	<b>Interobserver concordance (%)</b>	<b>Cohen's <math>\kappa</math></b>
Nucleus area	85	0.70
Nucleus perimeter	85	0.70
Nucleus circularity	96	0.93
Nucleus caliper, max	85	0.70
Nucleus caliper, min	89	0.78
Nucleus eccentricity	96	0.93
Cell area	85	0.70
Cell perimeter	85	0.70
Cell circularity	93	0.85
Cell caliper, max	85	0.70

Cell caliper, min	85	0.70
Nucleus to cell area ratio	96	0.93

396 Table 2. Interobserver concordance and Cohen's kappa statistics in classification of  
 397 each morphometric variable as above or below the median value.

398

	<b>nBAP-1 high (n=13)</b>	<b>nBAP-1 low (n=14)</b>	<b>P</b>
Nucleus area, $\mu\text{m}^2$ (SD)	24.31 (4.38)	28.34 (3.40)	0.013
Nucleus perimeter, $\mu\text{m}$ (SD)	19.61 (1.78)	21.37 (1.28)	0.0066
Nucleus circularity	0.76 (0.04)	0.75 (0.04)	0.41
Nucleus caliper, max $\mu\text{m}$ (SD)	7.52 (0.65)	8.21 (0.58)	0.0074
Nucleus caliper, min $\mu\text{m}$ (SD)	4.43 (0.59)	4.67 (0.36)	0.20
Nucleus eccentricity (SD)	0.76 (0.03)	0.77 (0.04)	0.52
Cell area, $\mu\text{m}^2$ (SD)	88.50 (15.10)	94.58 (12.42)	0.26
Cell perimeter, $\mu\text{m}$ (SD)	37.05 (3.26)	38.33 (2.53)	0.26
Cell circularity	0.77 (0.01)	0.77 (0.01)	0.70
Cell caliper, $\mu\text{m}$ (SD)	13.62 (1.22)	14.09 (0.97)	0.27
Cell caliper, $\mu\text{m}$ (SD)	9.00 (0.79)	9.29 (0.59)	0.30
Nucleus to cell area ratio	0.28 (0.03)	0.30 (0.02)	0.031

399 Table 3a.

400 Average values and Students T-tests of cell morphometric variables in tumors of high  
 401 versus low nBAP-1 expression. SD, standard deviation.

402


	<b>Gene expression class 1a or 1b (n=15)</b>	<b>Gene expression class 2 (n=12)</b>	<b>P</b>
Nucleus area, $\mu\text{m}^2$ (SD)	24.89 (4.40)	28.28 (3.59)	0.041
Nucleus perimeter, $\mu\text{m}$ (SD)	19.84 (1.76)	21.37 (1.39)	0.0022
Nucleus circularity	0.76 (0.04)	0.75 (0.04)	0.42

Nucleus caliper, max $\mu\text{m}$ (SD)	7.59 (0.63)	8.23 (0.63)	0.016
Nucleus caliper, min $\mu\text{m}$ (SD)	4.48 (0.57)	4.65 (0.37)	0.39
Nucleus eccentricity (SD)	0.76 (0.03)	0.77 (0.04)	0.33
Cell area, $\mu\text{m}^2$ (SD)	89.90 (14.59)	93.83 (13.16)	0.48
Cell perimeter, $\mu\text{m}$ (SD)	37.34 (3.13)	38.18 (2.70)	0.47
Cell circularity	0.77 (0.01)	0.77 (0.01)	0.64
Cell caliper, max $\mu\text{m}$ (SD)	13.71 (1.15)	14.06 (1.05)	0.42
Cell caliper, min $\mu\text{m}$ (SD)	9.23 (0.61)	9.23 (0.61)	0.62
Nucleus to cell area ratio	0.28 (0.03)	0.30 (0.02)	0.024

403 Table 3b.

404 Average values and Students T-tests of cell morphometric variables in tumors of gene

405 expression class 1a or 1b versus 2. SD, standard deviation.



406

407 Figure 2.


408 Receiver operating characteristics (ROC) of the mean nucleus area, nucleus  
 409 perimeter, nucleus max caliper and nucleus to cell area ratio in the training cohort  
 410 ( $n=13$ ), with equal emphasis on sensitivity and specificity for the development of  
 411 metastasis. Mean nucleus area (blue line) achieved an area under the curve (AUC) of  
 412 0.67 (sensitivity 67 %, specificity 50 %,  $p=0.40$ ) at threshold  $27.5 \mu\text{m}^2$ ; Mean nucleus  
 413 perimeter (pink line) achieved an area under the curve (AUC) of 0.73 (sensitivity 67  
 414 %, specificity 70 %,  $p=0.24$ ) at threshold  $21.5 \mu\text{m}$ ; Mean nucleus max caliper (green  
 415 line) achieved an area under the curve (AUC) of 0.80 (sensitivity 67 %, specificity 90  
 416 %,  $p=0.13$ ) at threshold  $8 \mu\text{m}$ ; and mean nucleus to cell area ratio (orange line)  
 417 achieved an area under the curve (AUC) of 0.60 (sensitivity 67 %, specificity 50 %,  
 418  $p=0.61$ ) at threshold 0.28.  
 419

	Regression coefficient, $\beta$ (SE)	Wald statistic	<i>P</i>	Hazard coefficient, Exp( <i>b</i> ) (95 % CI)
<b>Univariate Cox proportional hazards</b>				
Nucleus area $\geq$ median	0.2 (0.7)	0.05	0.83	1.17 (0.3–4.8)
Nucleus perimeter $\geq$ median	0.9 (0.7)	1.5	0.22	2.5 (0.6–10.4)
Nucleus caliper, max $\geq$ median	0.9 (0.7)	1.5	0.22	2.5 (0.6–10.4)
Nucleus to cell area ratio $\geq$ median	0.4 (0.7)	0.4	0.52	1.6 (0.4–5.9)

420 Table 4.

421 Cox Proportional Hazards analysis of the association between metastasis-free survival  
 422 and cell morphometric variables. No method was individually associated with  
 423 shortened metastasis-free survival.  
 424 SE, standard error.




425





426

427 Figure 3.

428 Kaplan-Meier curves, cumulative metastasis-free survival. A) Patients with tumors  
429 with high nBAP-1 expression (yellow) versus low (blue), as defined by digital image  
430 analysis using a mean of <30 % stained tumor nuclei as cutoff (Log-Rank p=0.002).  
431 B) Patients with tumors of gene expression class 1a or 1b (yellow) versus 2 (blue,  
432 Log-Rank p=0.004). C) Patients in the validation cohort ( $n=14$ ) with mean nucleus  
433 max caliper  $\leq 8 \mu\text{m}$  (yellow) versus  $> 8 \mu\text{m}$  (blue), which was the threshold  
434 established in the training cohort (Log-Rank p=0.05).









Number at risk

Low	14	3	2	1	1	1	1	1
High	13	3	2	1	1	1	1	1



Number at risk

2	12	2	2	1	1	1	1	1
1a or 1b	15	4	2	1	1	1	1	1



Number at risk

$> 8 \mu\text{m}$	3	1	1	2	1	1	1	1
$\leq 8 \mu\text{m}$	11	5	3	2	1	1	1	1